Shareprice
13 Jul 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide invites to presentation of FG001 results from the first clinical trial in aggressive brain cancer on 17 May 2022

News


May 6, 2022

Copenhagen, Denmark, 6 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) invites to a presentation of the results from the clinical trial of FG001 used to guide surgery in patients with aggressive high-grade glioma brain cancer, which will first be presented at the 68th Scandinavian Neurosurgical Society (SNS) Congress held 14-16 May 2022, in Bergen, Norway

As a follow-up on the presentation done by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen in Bergen, FluoGuide hereby invites to an online presentation of the same data that will be presented at the SNS congress. The online presentation with subsequent discussion, will be held on 17 May at 2.00 pm CEST.

The agenda is as followed:
Welcome by Morten Albrechtsen, CEO.
Presentation by Principal Investigator, Chief surgeon Jane Skjøth-Rasmussen, MD, PhD
Open up for Q&A
Future clinical trials in brain cancer by Morten Albrechtsen, CEO
Closing remarks by Morten Albrechtsen, CEO

Together with Principal Investigator, Chief Surgeon Jane Skjøth-Rasmussen, PhD (Rigshospitalet), Andreas Kjær, Professor and CMO, and Morten Albrechtsen, CEO will also participate in the presentation and discussion.

To register for the online presentation, please register at: www.ir.live/fluoguide

To call in via phone, please, use the following details: 
Attendee Dial-in Number: +1 (312) 248-9348
Attendee Dial-in ID Number: 536473
Attendee Dial-in Passcode: 9585

Resume of the trial:
In total, 40 patients have been administered FG001 that has been shown to be safe and well-tolerated. No serious drug related adverse events have been reported. Only a few drug-related adverse events were reported as grades 1 or 2, and no pattern or dose relation was observed

The pharmacokinetic (PK) profile for FG001 was assessed for all dose levels. FG001 showed dose-dependent increases in exposure across dose levels in a linear manner.

Tumor-to-background ratio (TBR) is a measure of the contrast. At the optimal dose and time, 36 mg administered the evening before the surgery, all patients revealed a clinically relevant TBR value.

The histology samples from dose 36 mg, evening, and dose 48 mg, evening, have been unblinded and analyzed. The histology results confirm that FG001 lights up aggressive brain cancer.